Action VERV VERVE THERAPEUTICS, INC.
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Autres langues Verve Therapeutics, Inc.

Actions

VERV

US92539P1012

Marché Fermé - Nasdaq
Autres places de cotation
 22:00:00 12/06/2024 		Varia. 5j. Varia. 1 janv.
5,59 USD +4,88 % Graphique intraday de Verve Therapeutics, Inc. +4,68 % -59,90 %
10/06 Transcript : Verve Therapeutics, Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-10-2024 08:00 AM
31/05 Verve Therapeutics nomme Troy Lister directeur scientifique MT

Autres langues

Recherche
Voir les résultats
Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !
Inscription 100% Gratuite
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Verve Therapeutics Names Troy Lister Chief Scientific Officer
Verve Therapeutics, Inc. Announces Chief Scientific Officer Changes
Verve Therapeutics Announces Leadership Update
Verve Therapeutics, Inc. Announces Executive Changes
Verve Therapeutics to Participate in Upcoming Investor Conferences
Verve Therapeutics : An investigational in vivo base editing medicine targeting ANGPTL3, VERVE-201, achieves precise, and durable liver editing in nonclinical studies
Verve Therapeutics : Proof of concept for in vivo Base Editing to Inactivate the PCSK9 Gene and Lower LDL Cholesterol in Humans
Verve Therapeutics : Characterization of Guide RNA Site Consistency Across Ancestries and the Potential for Off Target Editing with the Clinical Stage Base Editing Medicine, VERVE 101
Verve Therapeutics CFO Andrew Ashe Executes Purchase of 76,000 Shares of Common Stock; Shares Jump Premarket
Verve Therapeutics : Characterization of Guide RNA Site Consistency Across Ancestries and the Potential for Off Target Editing with the Clinical Stage Base Editing Medicine, VERVE 101
Verve Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
Verve Therapeutics: Q1 Earnings Snapshot
Verve Therapeutics Announces Pipeline Progress and Reports First Quarter 2024 Financial Results
Verve Therapeutics Announces Dosing of First Patient in Heart-2 Phase 1b Clinical Trial Evaluating VERVE-102
Verve Therapeutics Announces Dosing of First Patient in Heart-2 Phase 1b Clinical Trial Evaluating VERVE-102
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Wolf Haldenstein Adler Freeman & Herz LLP announces that it is investigating Verve Therapeutics, Inc. for potential violations of federal securities laws
Sector Update: Health Care Stocks Slide Late Afternoon
Top Midday Decliners
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action VERV
  4. Actualités Verve Therapeutics, Inc.
  5. Autres langues